Posted innews Oncology Otorhinolaryngology
Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer
A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific comorbidities.